This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

To evaluate the soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor
(PlGF), and sFlt-1/PlGF ratio for the prediction of early- and late-onset preeclampsia
in a high-risk cohort.

Conclusions

Low serum PlGF concentration predicts early-onset preeclampsia from the second trimester
and elevated serum sFlt-1/PlGF ratio from 26 to 28 weeks of gestation. Elevated serum
sFlt-1 concentration in the first trimester in women who later develop late-onset,
severe preeclampsia may suggest different etiology compared to the late-onset non-severe
form of the disease.

Keywords:

Background

Preeclampsia is one of the leading causes of maternal and fetal morbidity and mortality.
It is a multiorgan disease, defined according to new onset hypertension and proteinuria
developing after 20 weeks of gestation [1]. Although the pathogenesis of the disorder starts much earlier in pregnancy, and
a number of known clinical risk factors exist (e.g. obesity, primiparity, and a history
of preeclampsia in multiparous women), there is no established way to predict the
disorder in clinical practice.

The etiology and pathogenesis of preeclampsia is not completely understood, but it
originates in the placenta, and maternal endothelium is the target of the disease
[2,3]. Dysregulation and imbalance of placental proangiogenic and antiangiogenic vasoactive
agents, soluble fms-like tyrosine kinase 1 (sFlt-1), vascular endothelial growth factor
(VEGF), and placental growth factor (PlGF) play a significant role in the pathogenesis
[4-6].

In the early first trimester of normal pregnancy sFlt-1 concentration is over tenfold
and PlGF over twofold higher than in non-pregnant state. In pregnancies ending in
early miscarriage both sFlt-1 and PlGF concentrations, measured at gestational weeks
six to ten, are significantly lower than in pregnancies with live birth [7]. After the first trimester sFlt-1 stays constant and PlGF increases until the end
of the second trimester. During the last two months of a normotensive pregnancy the
level of sFlt-1 increases and the level of PlGF decreases in maternal blood [8,9]. These changes occur earlier and are more pronounced in women who will develop preeclampsia
[8]. Moreover, these changes may be further exaggerated in pregnancies with an early-onset
of preeclampsia, and in preeclamptic pregnancies associated with small for gestational
age fetus [8]. Therefore, these vasoactive agents may be promising biomarkers for predicting preeclampsia
in early gestation. According to earlier studies PlGF concentrations may be significantly
lower already from the late first trimester in women who will developed preeclampsia.
Changes in the sFlt-1 concentrations occur later [10]. Accurate prediction of preeclampsia would be essential to identify women who benefit
most from intensive monitoring allowing rapid intervention with therapeutic procedures
when necessary. Low dose aspirin, started before 16 weeks of gestation, may be effective
in prevention, or at least delay the onset of early-onset and severe preeclampsia
in high-risk women [11,12]. However, it is not known who would benefit most from aspirin treatment.

We hypothesize that PlGF and sFlt-1 can be used as markers in the prediction of pre-eclampsia.
Our aim was to study concentrations of sFlt-1 and PlGF and their ratio (sFlt-1/PlGF)
in prospectively collected serial serum samples in a cohort of pregnant women with
clinical risk factors for preeclampsia, and controls with special reference to early-
and late-onset disease.

Methods

The PREDO project

This nested case–control study is a part of a multidisciplinary PREDO Project (Prediction
and Prevention of Preeclampsia) approved by the Ethics Committee of Obstetrics and
Gynecology Hospital District of Helsinki and Uusimaa. The study cohort was collected
prospectively between September 2005 and June 2009 in ten participating hospital maternity
clinics. The PREDO Project has been previously described in detail [11]. Briefly, we recruited 947 pregnant women with clinical risk factors for preeclampsia,
and 117 pregnant women without known clinical risk factors for preeclampsia served
as a control group. The recruitment took place at the time of the first ultrasound
screening at 12 + 0 to 14 + 0 (weeks + days) of gestation in one of ten Finnish hospital
maternity clinics participating in the PREDO Project; Women’s Hospital, Midwifery
Institute (Kätilöopisto) Maternity hospital and Jorvi Hospital at Helsinki University
Central Hospital, Kanta-Häme Central Hospital, Päijät-Häme Central Hospital, Tampere
University Hospital, Kuopio University Hospital, Northern Karelia Central Hospital,
Hyvinkää Hospital and Iisalmi Hospital. All women with a bilateral diastolic notch
in the uterine artery Doppler velocimetry at 12–14 weeks of gestation were included
in the medication group (n = 152) and randomised to acetylsalicylic acid or placebo.
All of these women gave blood samples for biochemical analyses at three timepoints
during the pregnancy. The other women for venipuncture were selected randomly: after
a woman was included in medication group the next participant recruited with risk
factors (without aforementioned ultrasound finding) gave blood samples at three timepoints
during the pregnancy. A written informed consent was obtained from all participants
before entering the study.

Data collection and diagnosis of preeclampsia

Pregnancy data were collected from the medical records of maternity clinics and hospitals.
Pregnancy outcomes were ascertained before biochemical analyses by a jury of two medical
doctors and a midwife who met face-to-face and agreed upon the diagnosis of each participant
based on criteria described above.

Subcohort for serum sFlt-1 and PlGF measurements

We included in this substudy 26 women with clinical risk factors for preeclampsia
who eventually developed the disease. All women whose preeclampsia diagnosis was ascertained
by the jury at the time these biochemical analyses were started, were included. Twenty-six
women with clinical risk factors but without preeclamptic pregnancy, chosen by computerized
randomization, formed a first control group. Fifty-three women without clinical risk
factors and without preeclamptic pregnancy formed a second control group. One woman
without clinical risk factors developed preeclampsia and she was included in the group
of women with preeclampsia. Preeclamptic women were categorized by the onset and severity
of the disease.

We were able to rule out smoking as a confounding factor, since it was an exclusion
criteria for the high risk women. For those women in the second control group, who
did not have known risk factors for preeclampsia, smoking was not an exclusion criteria.
However, all women filled in a questionnaire concerning their medical history. According
to that, from the fifty-three women in the second control group, six smoked during
the index pregnancy.

Statistical analysis

We analysed data with the SPSS 19.0 program. For comparisons between groups Students
t-test and ANOVA were used as appropriate. Bonferroni adjustment was used for multiple
comparisons. Since the sizes of the groups differed, we used nonparametric Kruskal-Wallis
test, and for corrected: post hoc test pairwise comparisons with adjusted significance,
to compare concentrations (PlGF and sFlt-1) and sFlt-1/PlGF ratio between the four
groups.

For comparison of sequential changes of PlGF and sFlt-1 concentrations, and sFlt-1/PlGF
ratio between groups from first to second, and from second to third measurement, the
change of the concentration or ratio between measurements was calculated for each
individual. For comparison of these changes between the four groups we used nonparametric
Kruskal-Wallis test. Receiver-operating characteristic (ROC) analysis was performed
to determine the predictive value of PlGF and sFlt-1/PlGF ratio at 18 + 0 to 20 + 0,
and 26 + 0 to 28 + 0 weeks of gestation.

Results

Six women developed early-onset preeclampsia (onset before 34 weeks of gestation),
and twenty-one women developed late-onset disease (onset after 34 weeks of gestation).
In the late-onset group, eight women were diagnosed with severe, and thirteen with
non-severe preeclampsia. In the early-onset group all six women developed severe form
of the disease.

The clinical characteristics of the study groups are presented in Table 2.

There were no significant differences in the gestational age at sampling between the
four groups. In the early-onset preeclampsia group the third samples were drawn at
26.0-26.9 weeks of gestation, and diagnoses of preeclampsia were made at 30.7-33.3
weeks of gestation. We excluded the measurement at 27 weeks of gestation in one woman
who was diagnosed with early-onset preeclampsia on the same day the blood sample was
drawn. In the other women proteinuria was not evident at the time of blood sampling.

sFlt-1

Serum sFlt-1 concentration was significantly higher in women who later developed early-onset
preeclampsia compared to women who developed late-onset preeclampsia and to women
in the two control groups at 26 + 0 to 28 + 0 weeks of gestation (Table 3). There were no differences between women with late-onset preeclampsia and control
groups at any time point (Figure 1). Those women who developed late-onset, severe preeclampsia (n = 8) had significantly
higher sFlt-1 concentration than women who were diagnosed with late-onset, non-severe
(n = 13) form of the disease at 12 + 0 to 14 + 0, 18 + 0 to 20 + 0, and 26 + 0 to
28 + 0 weeks of gestation (Table 4). In the late-onset preeclampsia subgroup birthweight standard deviation (SD), calculated
according to Finnish standards [13], was significantly lower in women with severe form of the disease compared to women
with non-severe form (birth weight SD −1.0 (SD 0.9), 0.2 (SD 1.0) p = 0.01 respectively).
The body mass index (BMI) was significantly higher in women who developed late-onset
non-severe, preeclampsia, compared to women who developed late-onset, severe preeclampsia
(BMI 33.6 (SD 7.0), 26.9 (SD 5.8), p = 0.03, respectively).

Table 3.Concentrations of placental growth factor, soluble vascular endothelial growth factor
receptor-1 and their ratio in three different timepoints during pregnancy

The sequential changes in the sFlt-1 concentrations between groups were not significant
between the first and the second measurements. The sequential change of sFlt-1 concentration
was significantly higher in the early-onset preeclampsia group compared to the other
groups between the second and third measurements (p = 0.002).

PlGF

Serum PlGF concentration was significantly lower in women who went on to develop early-onset
preeclampsia compared to the other groups at 18 + 0 to 20 + 0, and at 26 + 0 to 28 + 0
weeks of gestation (Table 3). We did not find any differences in the serum PlGF concentration between the study
groups at 12 + 0 to 14 + 0 weeks of gestation, or between women with late-onset preeclampsia
and the two control groups at any time point (Figure 1). At 26 + 0 to 28 + 0 weeks of gestation the PlGF concentration in controls with
risk factors was significantly lower than in controls without risk factors.

There was a significant difference in the sequential changes of the serum PlGF concentration
between the first and the second (p = 0.02), and the second and the third (p < 0.001)
measurement when the early- onset preeclampsia group was compared with the late-onset
and the two control groups. Between the second and third measurement the PlGF concentration
increased over 100% in the late-onset preeclampsia group and the two control groups,
whereas in the early-onset preeclampsia group it decreased 40%.

sFlt-1/PLGF ratio

The serum sFlt-1/PlGF ratio at 26 + 0 to 28 + 0 weeks of gestation was significantly
higher in the early-onset preeclampsia group compared to the other groups (Table 3). We did not find any differences in the serum sFlt-1/PlGF ratio between the four
groups at 12 + 0-14 + 0 or at 18 + 0 to 20 + 0 weeks of gestation, or between the
late-onset preeclampsia group and control groups at any time point (Figure 1).

Between first and second measurements the sequential changes between groups were not
different. The sequential change of sFlt-1/PlGF ratio in the early-onset preeclampsia
group was significantly higher compared to the late-onset preeclampsia and control
groups between second and third measurements (p = 0.002).

After adjusting for BMI before pregnancy the differences in sFlt-1, PlGF, or the sFlt-1/PlGF
ratio between groups remained unchanged.

We found a negative correlation between birth weight SD score and the serum sFlt-1/PlGF
ratio at all timepoints in women who developed preeclampsia. Correlation was strongest
at 26 + 0 to 28 + 0 weeks of gestation (Spearman’s correlation coefficient −0.403,
p = 0.04; -0.452 p = 0.02, and −0.673, p = 0.0002 at 12 + 0 to14 + 0, 18 + 0 to 20 + 0,
and 26 + 0 to 28 + 0 weeks of gestation, respectively). We did not find any correlation
between birth weight SD score and the serum sFlt-1/PlGF ratio in the two control groups.

Receiver operating characteristic analyses

Receiver operating characteristic (ROC) curves (Figure 2) demonstrate the performance of these markers in prediction of early-onset preeclampsia.
PlGF (area under the curve (AUC) 91.4%, p = 0.0007, 95% CI 83.4-99.5) has a better
predictive value at 18 + 0 to 20 + 0, weeks of gestation than sFlt-1/PlGF ratio (AUC
78.6%, p = 0.02, 56.3-98.9). A cut-off point of PlGF concentration 83.9 pg/ml finds
women with future early-onset preeclampsia with a 83.3% sensitivity and 91.1% specificity,
with positive predictive value (PPV) 38% and negative predictive value (NPV) 94%.
At the 26 + 0 to 28 + 0 weeks of gestation sFlt-1/PlGF ratio performed slighty better
than PlGF (AUC 100.0%, p = 0.0007, 100.0-100.0, and 99.8%, p = 0.0008, 99.0-100.5,
respectively), and better than sFlt1-1 (AUC 94.4%, p = 0.003, 84.6-100.0). At 26 + 0
to 28 + 0 weeks of gestation all women who developed early-onset preeclampsia and
one woman who developed severe late-onset preeclampsia had serum sFlt-1/PlGF ratio
over 30. All women who did not develop preeclampsia or who developed late-onset, non-severe
form of the disease had sFlt-1/PlGF ratio under 15 at 26 + 0 to 28 + 0 weeks of gestation.
If the cut-off point were set to 40, women who later develop early-onset preeclampsia
would have been found with 100% sensitivity and specifity (PPV 100%, NPV100%). For
PlGF with cut-off point set to 90.4, PPV was 80% and NPV 100%.

Discussion

In this nested case–control study performed in high risk women we found lower PlGF
concentration from 18 + 0 to 20 + 0 weeks of gestation in sera of women who later
developed early-onset preeclampsia. Serum sFlt-1/PlGF ratio over 40 at 26 + 0 to 28 + 0
weeks of gestation has high specificity and sensitivity in identifying women who developed
early-onset disease. Women who were later diagnosed with late-onset, severe form of
preeclampsia had significantly increased levels of sFlt-1 already at 12 + 0 to 14 + 0
weeks of gestation compared to women with late-onset, non-severe form of the disease.
This is a new finding in a study with a small sample size and needs to be confirmed
in a larger study population.

We would like to emphasize that these findings are likely to be specific to high risk
women.

Earlier studies have reported that the ratio of sFlt-1/PlGF is a better predictor
of early preeclampsia than the two markers alone [14]. We found that serum sFlt-1/PlGF ratio was significantly higher from 26 + 0 to 28 + 0
weeks of gestation in women who later developed early-onset preeclampsia compared
to the three other study groups. However, in our study PlGF alone was a better predictor
of early pre-eclampsia at 18 + 0 to 20 + 0 weeks of gestation. In the study of Levine
and coworkers [6] sFlt-1/PlGF ratio was significantly higher already from 17 to 20 weeks of gestation
in women who developed preterm preeclampsia. Moore Simas and coworkers [15] found that sFlt-1/PlGF ratio measured at 22 to 26 weeks of gestation was highly predictive
of early-onset preeclampsia. In these two studies significantly increased sFlt-1/PlGF
ratio was also found at 25 to 30 weeks of gestation in women destined to develop late-onset
preeclampsia. In contrast, we did not observe significant difference in sFlt-1/PlGF
ratio between the late onset preeclampsia group and the two control groups at any
of the measured time points. In our study all women who were destined to develop early-onset
preeclampsia could be identified at 26 + 0 to 28 + 0 weeks of gestation, 4.0 to 6.3
weeks before the diagnosis of preeclampsia, by sFlt1/PlGF ratio, cut-off point set
so, that no false positives existed. In other words, we were able to identify the
developing early-onset disease among the high-risk population at least one month before
the clinical diagnosis was made. From the clinical perspective, these findings are
significant by helping obstetricians to make decisions on the management of the high-risk
women; how intensive follow-up is required, whether hospitalization is essential,
and whether it is necessary to be prepared to early delivery in a tertiary care center.

Interestingly, recent studies have proposed that sFlt-1/PlGF ratio may be useful not
only as a predictor of preeclampsia but also in the differential diagnosis of hypertensive
diseases of pregnancy, and, as well, serve as a prognostic parameter in patients with
established preeclampsia [16,17]. Verlohren and coworkers proposed that sFlt-1/PlGF ratio may be used in individualized
risk stratification in patients with clinical preeclampsia, and clinical management
can be adapted accordingly [17]. Rana and coworkers [18], studied angiogenic factors in 616 women with a suspected preeclampsia, and found
that in early-onset (<34 weeks) disease sFlt-1/PlGF ratio predicts adverse outcome
occurring within two weeks. Even in association with the atypical presentation of
preeclampsia, with relatively normal blood pressure or with no proteinuria, sFlt-1/PlGF
ratio performed well. Rana and coworkers showed an inverse correlation between sFlt-1/PlGF
ratio and the remaining duration of pregnancy.

Many studies have demonstrated low levels of PlGF already in the first trimester in
women who later developed preterm or term preeclampsia [10,19-22]. Cowans and coworkers [23] and Noori and coworkers [24] found significantly lower PlGF levels from the first trimester of pregnancy in women
who later developed early-onset or preterm preeclampsia, but not in women with term
preeclampsia. We found significant differences in the serum PlGF concentrations between
the early-onset preeclampsia group and the three other study groups, however, not
earlier than 18 + 0 to 20 + 0 weeks of gestation. We showed that at 18 + 0 to 20 + 0
weeks of gestation, 7.3 to 13.4 weeks before the diagnosis, PlGF could predict early-onset
preeclampsia in our high-risk population with an AUC 91.4%. The performance of PlGF
as a predictive marker improves over the course of pregnancy so that, 26 + 0 to 28 + 0
weeks of gestation, PlGF has AUC 99.8% (PPV 80%, NPV 100%) in predicting early-onset
preeclampsia in this study population. However, during the second half of pregnancy,
sFlt-1/PlGF ratio performed even better (PPV 100%, NPV 100%).

Our study is in line with most earlier studies in finding significant differences
of sFlt-1 concentration between women who are destined to develop preeclampsia and
controls not earlier than during the second half of pregnancy [15,20,25]. However, some studies have reported elevated sFlt-1 concentration already from thirteen
to twenty weeks of gestation [18,26-28]. Analyses performed using first trimester serum samples have resulted in negative
findings [19,21,22]. Vatten and coworkers [29] studied a cohort consisting of 154 women who later developed preterm preeclampsia
(diagnosis before 37 weeks of gestation), 190 women with term preeclampsia (diagnosis
after 37 weeks of gestation) and 392 control women. They found that sequential change
of sFlt-1 concentration between first and second trimester strongly predicts preeclampsia.
Moreover, in the preterm preeclampsia group the sequential change in sFlt-1 concentration
was steeper than in the term preeclampsia group. One major difference between our
study and the studies of others was that we did not find any differences between the
late onset preeclampsia and the two control groups at any of the measured time points.

Vasoactive agents may behave differently not only in early-onset and late-onset preeclampsia,
but also in severe and non-severe cases. This might reflect the differences in pathogenesis
of subtypes of preeclampsia. Early-onset preeclampsia is considered more as a placental
disease whereas late-onset more as a maternal disease. Early-onset preeclampsia is
considered a consequence of abnormal placentation and it has often a familial predisposition
suggesting a genetic component and a high recurrence risk [30]. In the early-onset form of the disease placental insufficiency often results in
fetal growth restriction. Late-onset disease emerges from maternal predisposing risk
factors, eg. metabolic factors, associated with obesity, chronic hypertension, diabetes,
and interacting with a normal placenta [30]. Our finding of significantly higher serum sFlt-1 concentration in maternal serum
already from 12 + 0 to 14 + 0 weeks of gestation in women who developed late-onset,
severe, preeclampsia compared to women who developed late-onset, non-severe form of
the disease could reflect this phenomenon. Women with late-onset, severe preeclampsia
gave birth to significantly lighter newborns, whereas women with late-onset, non-severe
form of the disease had significantly higher BMI in early pregnancy arguing for a
metabolic etiology.

The strength of our study is a well-characterized prospective cohort. However, we
acknowledge that the number of women who developed early-onset preeclampsia was small
even if we studied women with clinical risk factors for preeclampsia. One limitation
of our study is that we do not have serum samples available after 30 weeks of gestation.
Therefore we are not able to study how these biomarkers behave close to the diagnosis
of late-onset preeclampsia. Our prospective study reflects the true composition of
early-onset and late-onset preeclampsia in women at high-risk, which may explain differences
between the present and some earlier studies. If the proportion of women with early-onset
preeclampsia compared to women with late-onset preeclampsia is higher than usually
observed in the clinical practise, and the early- and late-onset preeclampsia groups
are analysed together, the results may be biased. Moreover, many preanalytical and
methodological differences may exist between studies. These include the different
sample material (plasma or serum) and the storage and handling of the samples. The
assays may have a different specificity and sensitivity and the study population may
differ between studies.

Conclusions

In conclusion, using serum PlGF we were able to identify already before 20 weeks of
gestation women who will develop early-onset preeclampsia. Even more accurately sFlt-1/PlGF
ratio identified those women who developed early-onset preeclampsia, weeks before
the onset of clinical disease.

The significantly increased serum sFlt-1 concentration already from the 12 weeks of
gestation in the late-onset, severe preeclampsia compared to late-onset non-severe
preeclampsia suggests for different pathological background in the late-onset subgroup.

Competing interests

Roche Diagnostics Ltd and Perkin Elmer Ltd paid Dr Pia M Villa’s travel expences to
medical meetings held in Germany and in Denmark during year 2012.

Authors’ contributions

The authors made the following substantial contributions to this work: concept and
design: PV, EH, KR, AKP, PT, EK, HL; analysis and interpretation of data: PV, EH,
AM, HL; drafting the article: PV, EH, HL; and revising the manuscript for intellectual
content: all authors. Final approval of the version to be published was given by all
authors.